Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia

por Collette, Y, Prébet, T, Goubard, A, Adélaïde, J, Castellano, R, Carbuccia, N, Garnier, S, Guille, A, Arnoulet, C, Charbonier, A, Mozziconacci, M J, Birnbaum, D, Chaffanet, M, Vey, N
Publicado 2015

A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia

por Saland, E, Boutzen, H, Castellano, R, Pouyet, L, Griessinger, E, Larrue, C, de Toni, F, Scotland, S, David, M, Danet-Desnoyers, G, Vergez, F, Barreira, Y, Collette, Y, Récher, C, Sarry, J-E
Publicado 2015

A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study

por Collignon, A., Hospital, M. A., Montersino, C., Courtier, F., Charbonnier, A., Saillard, C., D’Incan, E., Mohty, B., Guille, A., Adelaïde, J., Carbuccia, N., Garnier, S., Mozziconacci, M. J., Zemmour, C., Pakradouni, J., Restouin, A., Castellano, R., Chaffanet, M., Birnbaum, D., Collette, Y., Vey, N.
Publicado 2020